1. New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics

3. Program Agenda

4. PAD: Epidemiology and Burden

5. CAD and PAD: Overlapping Conditions

6. AHA/ACC Guidelines: Antiplatelet Agents

7. AHA/ACC Guidelines: Oral Anticoagulation

8. ESC Guidelines: Antiplatelet Agents

9. Aspirin in PAD

10. CAPRIE: Clopidogrel vs Aspirin

11. CHARISMA: Clopidogrel Plus Aspirin vs Aspirin Alone

12. CHARISMA: Patients With PAD

13. CHARISMA: Safety Results

14. PEGASUS-TIMI 54: MACE in Patients With PAD

15. PEGASUS-TIMI 54: Bleeding Events

16. EUCLID: Primary Efficacy Endpoint

17. Antiplatelet Therapy Challenges in PAD

18. WAVE: Oral Anticoagulation for PAD

19. ATLAS ACS 2—TIMI 51: Results

20. COMPASS: Trial Design

21. Combination of Factor Xa Inhibition and Antiplatelet Therapy

22. COMPASS MIND

23. VOYAGER PAD: Study Design

24. VOYAGER PAD: Study Design (cont)

25. Edoxaban: ePAD-Study

26. Conclusions

27. Conclusions (cont)